Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
What sector does Fulcrum Therapeutics Inc (FULC) operate in?
Fulcrum Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Fulcrum Therapeutics Inc (FULC) current stock price?
As of the latest data, Fulcrum Therapeutics Inc stock price is $3.77, with a previous close of $3.75. Fulcrum Therapeutics Inc gained $0.02 in the last trading session, representing a 0.53% increase.
What is Fulcrum Therapeutics Inc (FULC) current market capitalization?
Fulcrum Therapeutics Inc market cap is approximately 287.64 million.
What is Fulcrum Therapeutics Inc (FULC) Earnings Per Share (EPS)?
The trailing EPS is -$1.21, and the forward EPS is -$0.49.
What is Fulcrum Therapeutics Inc (FULC) EBITDA?
Fulcrum Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -19.69 million.
Does Fulcrum Therapeutics Inc (FULC) pay dividends?
No. Fulcrum Therapeutics Inc does not pay a dividend.
What is Fulcrum Therapeutics Inc (FULC) beta (volatility) score?
Fulcrum Therapeutics Inc has a beta of 2.581, indicating very high volatility compared to the market.
